These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 18841045)

  • 1. Histone deacetylase inhibitors in cancer therapy.
    Lee MJ; Kim YS; Kummar S; Giaccone G; Trepel JB
    Curr Opin Oncol; 2008 Nov; 20(6):639-49. PubMed ID: 18841045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational combinations using HDAC inhibitors.
    Bots M; Johnstone RW
    Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors: current status and overview of recent clinical trials.
    Ma X; Ezzeldin HH; Diasio RB
    Drugs; 2009 Oct; 69(14):1911-34. PubMed ID: 19747008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
    Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
    Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
    Giannini G; Cabri W; Fattorusso C; Rodriquez M
    Future Med Chem; 2012 Jul; 4(11):1439-60. PubMed ID: 22857533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDACi--going through the mechanisms.
    Wanczyk M; Roszczenko K; Marcinkiewicz K; Bojarczuk K; Kowara M; Winiarska M
    Front Biosci (Landmark Ed); 2011 Jan; 16(1):340-59. PubMed ID: 21196174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
    Slingerland M; Guchelaar HJ; Gelderblom H
    Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy.
    Zhang L; Han Y; Jiang Q; Wang C; Chen X; Li X; Xu F; Jiang Y; Wang Q; Xu W
    Med Res Rev; 2015 Jan; 35(1):63-84. PubMed ID: 24782318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A work in progress: the clinical development of histone deacetylase inhibitors.
    Marsoni S; Damia G; Camboni G
    Epigenetics; 2008; 3(3):164-71. PubMed ID: 18487953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors: overview and perspectives.
    Dokmanovic M; Clarke C; Marks PA
    Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
    Riester D; Hildmann C; Schwienhorst A
    Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors in cancer treatment.
    Vigushin DM; Coombes RC
    Anticancer Drugs; 2002 Jan; 13(1):1-13. PubMed ID: 11914636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoform-selective histone deacetylase inhibitors.
    Bieliauskas AV; Pflum MK
    Chem Soc Rev; 2008 Jul; 37(7):1402-13. PubMed ID: 18568166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
    Mazzone R; Zwergel C; Mai A; Valente S
    Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Therapies Targeting HDAC and IKK in Solid Tumors.
    Vancurova I; Uddin MM; Zou Y; Vancura A
    Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies.
    Singh A; Patel P; Jageshwar ; Patel VK; Jain DK; Kamal M; Rajak H
    Curr Cancer Drug Targets; 2018; 18(8):720-736. PubMed ID: 28669336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.